Google
SABSW Stock Price & Analysis — Sab Biotherapeutics Inc
SABSW FAQ
What is SABSW's ROE?
Sab Biotherapeutics Inc reports a Return on Equity (ROE) of -0.18%.
What is SABSW's dividend yield?
Sab Biotherapeutics Inc offers a dividend yield of 0.00%.
What is SABSW's Quality Score?
Our AI rates SABSW's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SABSW?
Our AI Timing Score for SABSW is 1 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
SABSW AI Analysis Summary
Our AI summary for SABSW: Sab Biotherapeutics Inc (NASDAQ). The stock currently trades at a P/E of 0.00, ROE of -0.18%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 1/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.02
Price
-0.01
(-28.87%)
Day Change
|
|
|---|
SABSW, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
38% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.02 |
| PBV / Sector |
N/A / N/A
|
| Earning Per Share | N/A |
| PE / Sector |
N/A / N/A
|
| PEG or PE/Growth / Sector |
N/A / N/A
|
| Average 1M Daily Value |
1754.650415000000
|
| Average 1W Daily Value |
3477.595240000000
|
| Timing Factors |
|
71% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 777 W 41st St., Miami Beach, FL, United States, 33140
Phone: 305 845 2813
Website: https://www.sab.bio
Employees: 86
Sector: -
Description: SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
